ZA202001884B - Rar selective agonists in combination with immune modulators for cancer immunotherapy - Google Patents

Rar selective agonists in combination with immune modulators for cancer immunotherapy

Info

Publication number
ZA202001884B
ZA202001884B ZA2020/01884A ZA202001884A ZA202001884B ZA 202001884 B ZA202001884 B ZA 202001884B ZA 2020/01884 A ZA2020/01884 A ZA 2020/01884A ZA 202001884 A ZA202001884 A ZA 202001884A ZA 202001884 B ZA202001884 B ZA 202001884B
Authority
ZA
South Africa
Prior art keywords
combination
cancer immunotherapy
selective agonists
immune modulators
rar selective
Prior art date
Application number
ZA2020/01884A
Other languages
English (en)
Inventor
Roshantha A Chandraratna
Martin E Sanders
Original Assignee
Io Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Therapeutics Inc filed Critical Io Therapeutics Inc
Publication of ZA202001884B publication Critical patent/ZA202001884B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2020/01884A 2017-08-31 2020-03-24 Rar selective agonists in combination with immune modulators for cancer immunotherapy ZA202001884B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762552814P 2017-08-31 2017-08-31
PCT/US2018/048876 WO2019046591A1 (en) 2017-08-31 2018-08-30 SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
ZA202001884B true ZA202001884B (en) 2021-10-27

Family

ID=65436409

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/01884A ZA202001884B (en) 2017-08-31 2020-03-24 Rar selective agonists in combination with immune modulators for cancer immunotherapy

Country Status (13)

Country Link
US (5) US10363272B2 (enExample)
EP (1) EP3675843A4 (enExample)
JP (1) JP2020532537A (enExample)
KR (1) KR20200044889A (enExample)
CN (1) CN111148514A (enExample)
AU (1) AU2018326617B2 (enExample)
CA (1) CA3073953A1 (enExample)
IL (1) IL272971A (enExample)
MX (1) MX2020002262A (enExample)
NZ (1) NZ761401A (enExample)
SG (1) SG11202001479RA (enExample)
WO (1) WO2019046591A1 (enExample)
ZA (1) ZA202001884B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510114A (ja) 2005-09-30 2009-03-12 ビテ ファーマシューティカルズ， インコーポレイテッド 特定のｒｘｒアゴニストによる癌治療
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
PL3368080T3 (pl) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
CN115227826A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
SG11201807250PA (en) 2016-03-10 2018-09-27 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
WO2019014492A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
JP2020532537A (ja) 2017-08-31 2020-11-12 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用
JP2024543621A (ja) 2021-12-07 2024-11-21 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用
JP2024544223A (ja) 2021-12-07 2024-11-28 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用
AU2023301379A1 (en) 2022-06-27 2024-12-19 Io Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof
KR102874422B1 (ko) 2022-11-04 2025-10-22 한국원자력연구원 무정전 전원을 갖는 환경방사선 감시시스템의 전원 시스템 및 그 방법

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576007A (en) 1976-02-11 1980-10-01 Beecham Group Ltd Hypolipidaemic compositions
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
ES2102195T3 (es) 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
CA2263817A1 (en) 1996-08-28 1998-03-05 Centre National De La Recherche Scientifique Therapeutic combinations of rar antagonists and rxr agonists and use thereof
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU774538B2 (en) 1999-06-11 2004-07-01 Allergan, Inc. Organosilyl compounds having nuclear hormone receptor modulating activity
WO2001007028A2 (en) 1999-07-23 2001-02-01 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
TWI281911B (en) * 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
EP1353217A1 (en) 2002-03-29 2003-10-15 JSR Corporation Optical alignment method and liquid crystal display element
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005046726A2 (en) 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
US7476673B2 (en) 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
JP2009510114A (ja) 2005-09-30 2009-03-12 ビテ ファーマシューティカルズ， インコーポレイテッド 特定のｒｘｒアゴニストによる癌治療
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
AR069747A1 (es) * 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
KR101577843B1 (ko) * 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ｏｘ４０ 수용체에 대한 결합 분자
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9446105B2 (en) * 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CA2899577C (en) 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2015138920A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN106459063A (zh) 2014-04-11 2017-02-22 北卡罗来纳-查佩尔山大学 Mertk‑特异性嘧啶化合物
WO2016015095A1 (en) 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
AU2015315435A1 (en) 2014-09-08 2017-03-23 Celgene Corporation Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JP6723164B2 (ja) 2014-12-25 2020-07-15 株式会社癌免疫研究所 Ｔ細胞集団の改変方法
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3267969A1 (en) * 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
CA2986765A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3337514B8 (en) 2015-08-18 2022-04-06 Rakuten Medical, Inc. Composition comprising a conjugate comprising a phthalocyanine dye linked to a targeting molecule for photoimmunotherapy
EP3344656A1 (en) * 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
SG11201802966TA (en) 2015-10-20 2018-05-30 Kite Pharma Inc Methods of preparing t cells for t cell therapy
PL3380086T3 (pl) * 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
EP3383908A1 (en) * 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
WO2017201200A1 (en) 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
KR20190017950A (ko) 2016-06-10 2019-02-20 아이오 테라퓨틱스, 인크. 암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제
WO2019014492A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
JP2020532537A (ja) 2017-08-31 2020-11-12 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト

Also Published As

Publication number Publication date
WO2019046591A1 (en) 2019-03-07
SG11202001479RA (en) 2020-03-30
US20190314415A1 (en) 2019-10-17
US20200138867A1 (en) 2020-05-07
NZ761401A (en) 2022-11-25
JP2020532537A (ja) 2020-11-12
US11786555B2 (en) 2023-10-17
US10532074B2 (en) 2020-01-14
AU2018326617A1 (en) 2020-02-27
EP3675843A1 (en) 2020-07-08
US20190060362A1 (en) 2019-02-28
AU2018326617B2 (en) 2022-12-01
MX2020002262A (es) 2020-07-20
US10532073B2 (en) 2020-01-14
EP3675843A4 (en) 2021-11-03
US10874694B2 (en) 2020-12-29
IL272971A (en) 2020-04-30
CN111148514A (zh) 2020-05-12
US20190343883A1 (en) 2019-11-14
KR20200044889A (ko) 2020-04-29
CA3073953A1 (en) 2019-03-07
US20210100844A1 (en) 2021-04-08
US10363272B2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
IL272971A (en) Selective RAR agonists and their combinations with immunomodulators for cancer immunotherapy
IL279230B (en) Methods related to crispr–cas, compositions and components for cancer immunotherapy
ZA202005298B (en) Combination tumor immunotherapy
ZA201807809B (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
ZA202103016B (en) Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
IL247066B (en) Cancer immunotherapy by combining local and systemic immune stimulation
IL265370B (en) Immune modulation with tlr9 agonists for cancer therapy
GB201408539D0 (en) Improvements in mobile payment systems
GB201521894D0 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
EP3512537C0 (en) T-CELL IMMUNOTHERAPY
GB201705228D0 (en) Systems and methods for providing payment hotspots
LT3317300T (lt) Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai
HK40031460A (en) Rar selective agonists in combination with immune modulators for cancer immunotherapy
SG11201605589PA (en) Device with positioning function, positioning result receiving device, and positioning result utilizing system
EP3134701A4 (en) Projectile arresting device and projectile arresting arrangement
PT3545109T (pt) Método in vitro para identificar adenomas colorretais ou cancro colorretal
EP3142698A4 (en) Immunotherapy with binding agents
HK40031060A (en) Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
HK40006312A (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
HK40031057A (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
HK40012361A (en) Immune modulation with tlr9 agonists for cancer treatment
PT3576907T (pt) Dispositivo de afiação
GB2563900B (en) Reflective apparatus
HK1231731A1 (en) Immunotherapy of cancer through combination of local and systemic immune stimulation
GB201503314D0 (en) Back station